secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001370053-25-000063
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio Q2 net loss narrows to $38.6M; rosnilimab Phase 2b RA data positive
------------------------------------------------------------------------------

- Net loss $38.6M ($1.34/sh) vs $46.7M ($1.71) YoY; collaboration revenue $22.3M, up from $11.0M.
- Cash & investments $293.7M as of June 30, 2025; cash runway through year-end 2027 reiterated.
- Rosnilimab RA Phase 2b shows JAK-like efficacy, durable off-drug response; UC Phase 2 enrollment complete, top-line Q4 2025.
- ANB033 (CD122 antagonist) to begin Phase 1b in celiac disease by Q4 2025; R&D event planned.
- Anticipate $75M GSK milestone in 2025 once Jemperli achieves $1B annual net sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000063/0001370053-25-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000063/anab-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001370053-25-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer